Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Steve's Channelling Thread -- Ignore unavailable to you. Want to Upgrade?

To: SBHX who wrote (7082)	11/2/2000 8:49:29 AM
From: xcr600	Respond to of 30051

no prob. I am done with them. eom

To: SBHX who wrote (7082)	11/2/2000 9:04:13 AM
From: Bosco	Read Replies (1) \| Respond to of 30051

<warning: shameless hype :)>Hi all - awhile back, someone has asked about CEGE. Just wanna update the interested parties here biz.yahoo.com as of this morning snapshot 10.5% of ABGX = 21.59 cash position = 8.29 last nite close 24 7/8 last Q burnrate ~8MM recent ER biz.yahoo.com recent hype factor :) biz.yahoo.com My take: I believe CEGE core technologies AAV and GVAX vaccine applications are a good bet. It has a good business model. Strong cash position. ABGX holding will flutuate, so it should not be used as "cash equivalence," as some people have tried. This is my only biotech holding for now, after selling others last week best, Bosco